HULUWA(SH:605199) Ge Long Hui A P P·2025-10-17 13:39Core Viewpoint - ST HuLuWa (605199.SH) aims to enhance its core competitiveness and accelerate drug development by integrating R&D resources and sharing R&D risks through a technical cooperation agreement with related parties [1] Group 1: Company Actions - The company held a special meeting of independent directors and an extraordinary board meeting on October 17, 2025, to approve the proposal for signing a technical cooperation development contract [1] - The expected total R&D cost for the projects "Ondansetron Oral Soluble Film" and "Ibutamoren Right-Arm Injection Concentrate Solution" is budgeted to not exceed 11.25 million yuan [1] - Following board approval, the company will sign a technical cooperation development contract with Kang Lianxian to jointly develop the aforementioned projects [1]